1. Search Result
Search Result
Results for "

synaptosome

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Peptides

5

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10772

    Calcium Channel Calmodulin Adenylate Cyclase Neurological Disease Inflammation/Immunology
    Albanin A, a flavonoid, suppresses glutamate release by decreasing Ca 2+/calmodulin/adenylate Cyclase 1 (AC1) activation in synaptosomes and exerts neuroprotective effect in vivo. Albanin A has anti-inflflammatory activity .
    Albanin A
  • HY-N2326

    nAChR Neurological Disease
    (±)-Anatoxin A fumarate is a natural alkaloid isolated from freshwater cyanobacterium.(±)-Anatoxin A fumarate is a potent nicotinic receptor agonist and exhibits Ki values of 1.25 nM and 1.84 μM for binding to putative α4β2-type nAChR and α7-type nAChR in rat brain membranes, respectively. (±)-Anatoxin A fumarate stimulates [ 3H]-dopamine release from rat striatal synaptosomes (EC50=134 nM) .
    (±)-Anatoxin A fumarate
  • HY-108973

    5-HT Receptor Neurological Disease
    CGP 15210G is an inhibitor of 5-HT reuptake. CGP 15210G inhibits the uptake of radiolabelled 5-HT into rat brain synaptosomes in vitro or ex vivo .
    CGP 15210G
  • HY-123199

    SABA

    Serotonin Transporter Neurological Disease
    Serotonin azidobenzamidine is an arylazido derivative of 5-hydroxytryptamine (HY-B1473A). Serotonin azidobenzamide competitively inhibits [3H]5-hydroxytryptamine uptake by rat cortical synaptosomes in the dark with a Ki of 130 nM .
    Serotonin azidobenzamidine
  • HY-16923A

    BIII-890 hydrochloride; BIII-890 CL

    Sodium Channel Neurological Disease
    Crobenetine hydrochloride (BIII-890 hydrochloride) is the hydrochloride form of Crobenetine (HY-16923). Crobenetine hydrochloride is a selective inhibitor for Na + channel. Crobenetine hydrochloride displaces 3HBTX from site 2 of the Na + channel (IC50=49 nM) in rat brain synaptosomes, exhibits only low binding affinity for other receptors and ion channels. Crobenetine hydrochloride protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents .
    Crobenetine hydrochloride
  • HY-16923

    BIII-890; BIII-890 CL free acid

    Sodium Channel Neurological Disease
    Crobenetine (BIII-890), a benzomorphan derivative, is a potent, selective, and highly use-dependent Na + channel blocker. Crobenetine displaces [3H]BTX from site 2 of the Na + channel (IC50=49 nM) in rat brain synaptosomes, yet exhibits only low binding affinity for other receptors and ion channels. Crobenetine protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents .
    Crobenetine
  • HY-129682

    5-HT Receptor Dopamine Receptor Adrenergic Receptor Neurological Disease
    LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with Ki values of 0.06 μM, 2.2 μM and 2.5 μM respectively .
    LY125180
  • HY-101334

    GlyT Neurological Disease
    MPDC is a potent and competitive inhibitor of the Na +-dependent high-affinity glutamate transporter in forebrain synaptosomes .
    MPDC
  • HY-101334A

    GlyT Neurological Disease
    MPDC hydrochloride is a potent and competitive inhibitor of the Na +-dependent high-affinity glutamate transporter in forebrain synaptosomes .
    MPDC hydrochloride
  • HY-101753A

    Cyanimipramine hydrochloride; Ro 11-2465 hydrochloride

    5-HT Receptor Neurological Disease
    Cianopramine hydrochloride (Cyanimipramine hydrochloride; Ro 11-2465 hydrochloride) is the hydrochloride form of Cianopramine (HY-101753). Cianopramine hydrochloride is an antidepressant, which selectively inhibits the serotonin uptake into synaptosomes .
    Cianopramine hydrochloride
  • HY-16934

    Cholinesterase (ChE) Neurological Disease
    ML352 is a noncompetitive inhibitor of the presynaptic choline transporter (CHT) with Ki values of 92 and 166 nM for HEK293 cells expressing human CHT and mouse forebrain synaptosomes, respectively .
    ML352
  • HY-145577

    Others Neurological Disease
    Lafadofensine is the monoamines reuptake inhibitor. Lafadofensine has th sufficient effects after short-term administration (extracted from patent WO2006121218A1, compound 1) .
    Lafadofensine
  • HY-145577A

    Others Neurological Disease
    Lafadofensine D-(-)-Mandelic acid is the monoamines reuptake inhibitor. Lafadofensine D-(-)-Mandelic acid has sufficient effects after short-term administration .
    Lafadofensine (D-(-)-Mandelic acid)
  • HY-B1237A

    Na+/K+ ATPase Cardiovascular Disease
    Suloctidil hydrochloride hydrochloride is an active agent against on Na+/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes. Suloctidil hydrochloride is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders.
    Suloctidil hydrochloride
  • HY-B0696A

    NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride

    GABA Receptor Neurological Disease
    Tiagabine hydrochloride is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [ 3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively .
    Tiagabine hydrochloride
  • HY-B0696B

    NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate

    GABA Receptor Neurological Disease
    Tiagabine hydrochloride hydrate is a potent and selective GABA uptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [ 3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively .
    Tiagabine hydrochloride hydrate
  • HY-B1237

    Na+/K+ ATPase Cardiovascular Disease
    Suloctidil is a new drug that is currently being evaluated in many clinical trials for use in dementia and thrombotic disorders Target: Effect of suloctidil on Na+/K+ ATPase activity and on membrane fluidity in rat brain synaptosomes.
    Suloctidil
  • HY-18610

    Ro 8-4650 hydrochloride

    Dopamine Transporter Neurological Disease
    Diclofensine hydrochloride (Ro-8-4650 hydrochloride) is a potent inhibitor of monoamine reuptake, blocking the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3, and 3.7 nM, respectively.
    Diclofensine hydrochloride
  • HY-18610A

    Ro 8-4650

    Dopamine Transporter Neurological Disease
    Diclofensine(Ro-8-4650) is a potent inhibitor of monoamine reuptake, blocking the uptake of dopamine, noradrenaline, and serotonin by rat brain synaptosomes with IC50 values of 0.74, 2.3, and 3.7 nM, respectively.
    Diclofensine
  • HY-B0696

    NO050328; NO328; TGB

    GABA Receptor Neurological Disease
    Tiagabine (NO050328) is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [ 3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively .
    Tiagabine
  • HY-B1287
    Citalopram hydrobromide
    Maximum Cited Publications
    6 Publications Verification

    (±)-Citalopram hydrobromide; Lu 10-171

    Serotonin Transporter Autophagy Neurological Disease Cancer
    Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect .
    Citalopram hydrobromide
  • HY-113273B

    Endogenous Metabolite Metabolic Disease
    Diadenosine pentaphosphate pentaammonium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .
    Diadenosine pentaphosphate pentaammonium
  • HY-113273C

    Endogenous Metabolite Metabolic Disease
    Diadenosine pentaphosphate pentalithium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .
    Diadenosine pentaphosphate pentalithium
  • HY-113273A

    Endogenous Metabolite Metabolic Disease
    Diadenosine pentaphosphate pentasodium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .
    Diadenosine pentaphosphate pentasodium
  • HY-B0696AS

    NO050328-dd4 hydrochloride; NO328-d4 hydrochloride; TGB-d4 hydrochloride

    GABA Receptor Isotope-Labeled Compounds Neurological Disease
    Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC50s of 67, 446 and 182 nM for [ 3H]GABA uptake in Synaptosomes, Neurons and Glia, respectively .
    Tiagabine-d4 hydrochloride
  • HY-N6776

    Potassium Channel Neurological Disease Cancer
    Penitrem A is an indole diterpene neurotoxic alkaloid produced by Penicillium, acts as a selective BK channel antagonist with antiproliferative and anti-invasive activities against multiple malignancies. Penitrem A increases the spontaneous release of endogenous glutamate, gamma-aminobutyric acid (GABA) and aspartate from cerebrocortical synaptosomes, and induces tremorgenic syndromes in animals .
    Penitrem A
  • HY-100968

    Dopamine Receptor Neurological Disease
    GBR 12783 dihydrochloride is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 dihydrochloride can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783 dihydrochloride
  • HY-W008610

    Dopamine Receptor Neurological Disease
    GBR 12783 is a specific, potent and selective dopamine uptake inhibitor that inhibits the [ 3H]dopamine uptake by rat and mice striatal synaptosomes with IC50s of 1.8 nM and 1.2 nM, respectively. GBR 12783 can improve memory performance and increase hippocampal acetylcholine release in rats .
    GBR 12783
  • HY-120170

    ASCT Adrenergic Receptor Dopamine Transporter Neurological Disease
    BMS-466442 is a potent and selective inhibitor of asc-1 (alanine serine cysteine transporter-1), with an IC50 of 11 nM. BMS-466442 inhibits [ 3H] D-serine uptake into rat brain synaptosomes, with an IC50 of 400 nM. BMS-466442 can be used for schizophrenia research .
    BMS-466442
  • HY-B1287R

    (±)-Citalopram hydrobromide(Standard); Lu 10-171 (Standard)

    Serotonin Transporter Autophagy Neurological Disease Cancer
    Citalopram (hydrobromide) (Standard) is the analytical standard of Citalopram (hydrobromide). This product is intended for research and analytical applications. Citalopram hydrobromide is a selective serotonin reuptake inhibitor (SSRI). Citalopram hydrobromide inhibits 5-HT uptake into synaptosomes with an IC50 of 1.8 nM. Citalopram hydrobromideinhibits the 5-HT uptake in rabbit blood platelets with an IC50 of 14 nM. Antidepressant effect .
    Citalopram hydrobromide (Standard)
  • HY-100838

    L-CCG III

    EAAT Neurological Disease
    cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC50: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na +-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .
    cis-α-(Carboxycyclopropyl)glycine
  • HY-103509

    GABA Receptor Neurological Disease
    NNC 05-2090 hydrochloride is a GABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50< /sub>: 10.6 μM). NNC 05-2090 hydrochloride also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases .
    NNC 05-2090 hydrochloride
  • HY-100769
    Hypidone hydrochloride
    1 Publications Verification

    YL0919

    5-HT Receptor Neurological Disease
    Hypidone hydrochloride (YL0919) is an orally active antidepressant agent with dual activity as a highly seletive 5-HT uptake blocker and an effective 5-HT1A?receptor agonist (Ki=0.19 nM). Hypidone hydrochloride inhibits the uptake of [ 3H]-5-HT into rat cerebral cortical synaptosomes and HEK293 cells with IC50s of 1.78 nM and 1.93 nM, respectively. Hypidone hydrochloride shows remarkable antidepressant effects in animal models and has the poential for the investigation of depressive disorder .
    Hypidone hydrochloride
  • HY-100928

    Calcium Channel Neurological Disease
    YS 035 hydrochloride is a Ca 2+ antagonist on cellular uptake and mitochondrial efflux of calcium ions. YS 035 hydrochloride inhibits Ca 2+ uptake by muscle cells and inhibits Na +/Ca 2+ exchange (Ki=28 µM). YS 035 hydrochloride is a useful tool for research on the mitochondrial Ca 2+ transport .
    YS 035 hydrochloride
  • HY-117160

    4-trans-hydroxycyclohexyl Glyburide; 4-trans-hydroxy Glibenclamide

    Potassium Channel Neurological Disease
    rac-trans-4-hydroxy Glyburide is an active metabolite of the SUR1/Kir6.2 sulfonylurea inhibitor glyburide (HY-15206). It is formed from glyburide by the cytochrome P450 (CYP) isoforms CYP2C8 and CYP2C9. rac-trans-4-hydroxy Glyburide inhibits glyburide binding to rat brain synaptosomes at the high and low affinity sites of SUR1/Kir6.2 with IC50 values of 0.95 and 100 nM, respectively.
    4-trans-Hydroxy-glibenclamide
  • HY-160959

    nAChR Neurological Disease
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
    AN317

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: